17beta-Hydroxysteroid dehydrogenase-3 deficiency: from pregnancy to adolescence
- PMID: 19498320
- DOI: 10.1007/BF03345738
17beta-Hydroxysteroid dehydrogenase-3 deficiency: from pregnancy to adolescence
Abstract
Objective: Aim of this study is to report on basal clinical phenotype and follow up after diagnosis, of patients with 17beta-hydroxysteroid-dehydrogenase type 3 (17beta-HSD3) deficiency in Italy.
Setting: Pediatric Endocrine Departments, University Hospitals.
Patients: The cases of 5 Italian subjects affected by 17beta-HSD3 deficiency are presented in this study.
Interventions: Laboratory and genetic assessment. Gonadectomy and female sex assignment (4 patients) or GnRH analog therapy to regress puberty and gender identity disorder (1 patient).
Results: Presentation lasted from pregnancy (pre-natal diagnosis of a 46,XY fetus with female external genitalia) to infancy (inguinal hernia containing testes/clitoromegaly) and adolescence (virilisation). All subjects but one (subject 1, Central-Northern Italy) were from small areas of Southern Italy. Endocrine data (baseline and/or stimulated testosterone/ Delta4-androstenedione ratio) were informative. Two girls were homozygous for 17beta-HSD3 gene mutations (G289S/G289S; R80W/R80W), while the others were compound heterozygous (IVS325+4 A>T/A203V; L212Q/M235V; R80W/A235E). Four patients were confirmed as females and were well-adjusted with assigned sex; gender identity disorder improved during treatment with GnRH analog in the last subject.
Conclusions: 17betaHSD3 deficiency may present from pregnancy to puberty for different clinical issues. Albeit testosterone/Delta4-androstenedione ratio represents the most accurate endocrine marker to diagnose the disorder, hCGstimulation is mandatory in pre-puberty. Molecular analysis of 17beta-HSD3 gene should be performed to confirm the diagnosis. Temporary GnRH analog treatment may regress gender identity disorder and provide time to confirm or change the birth sex assignment. Female individuals seems to be compliant with their sex, providing that virilisation does not occur. In Italy, the disorder seems to be more prevalent in the Southern regions and shows genetic heterogeneity.
Similar articles
-
46,XY disorder of sex development (DSD) due to 17β-hydroxysteroid dehydrogenase type 3 deficiency.J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):79-85. doi: 10.1016/j.jsbmb.2016.05.002. Epub 2016 May 6. J Steroid Biochem Mol Biol. 2017. PMID: 27163392 Review.
-
Clinical, endocrine, and molecular findings in 17beta-hydroxysteroid dehydrogenase type 3 deficiency.J Endocrinol Invest. 2008 Jan;31(1):85-91. doi: 10.1007/BF03345572. J Endocrinol Invest. 2008. PMID: 18296911 Review.
-
A novel missense (R80W) mutation in 17-beta-hydroxysteroid dehydrogenase type 3 gene associated with male pseudohermaphroditism.Eur J Endocrinol. 1998 Sep;139(3):330-3. doi: 10.1530/eje.0.1390330. Eur J Endocrinol. 1998. PMID: 9758445
-
17β-hydroxysteroid dehydrogenase type 3 deficiency: female sex assignment and follow-up.J Endocrinol Invest. 2020 Dec;43(12):1711-1716. doi: 10.1007/s40618-020-01248-y. Epub 2020 Apr 15. J Endocrinol Invest. 2020. PMID: 32297288
-
Clinical and molecular spectrum of patients with 17β-hydroxysteroid dehydrogenase type 3 (17-β-HSD3) deficiency.Arq Bras Endocrinol Metabol. 2012 Nov;56(8):533-9. doi: 10.1590/s0004-27302012000800012. Arq Bras Endocrinol Metabol. 2012. PMID: 23295294
Cited by
-
The use of quantitative ultrasound in a tertiary-level children hospital: role in the follow-up of chronically ill patients.J Ultrasound. 2022 Sep;25(3):563-570. doi: 10.1007/s40477-021-00624-5. Epub 2022 Jan 29. J Ultrasound. 2022. PMID: 35092603 Free PMC article.
-
Guidance for shared decision-making regarding orchiectomy in individuals with differences of sex development due to 17-β-hydroxysteroid dehydrogenase type 3 deficiency.Front Pediatr. 2025 Feb 20;13:1549400. doi: 10.3389/fped.2025.1549400. eCollection 2025. Front Pediatr. 2025. PMID: 40051913 Free PMC article. Review.
-
Management of disorders of sex development.Nat Rev Endocrinol. 2014 Sep;10(9):520-9. doi: 10.1038/nrendo.2014.108. Epub 2014 Jul 15. Nat Rev Endocrinol. 2014. PMID: 25022812 Review.
-
Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.J Endocrinol Invest. 2022 Jun;45(6):1255-1263. doi: 10.1007/s40618-022-01760-3. Epub 2022 Mar 2. J Endocrinol Invest. 2022. PMID: 35237949 Free PMC article.
-
A Novel Mutation Causing 17-β-Hydroxysteroid Dehydrogenase Type 3 Deficiency in an Omani Child: First Case Report and Review of Literature.Oman Med J. 2015 Mar;30(2):129-34. doi: 10.5001/omj.2015.27. Oman Med J. 2015. PMID: 25960839 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical